Compare NCSM & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCSM | THAR |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 90.8M |
| IPO Year | 2017 | 2022 |
| Metric | NCSM | THAR |
|---|---|---|
| Price | $39.01 | $3.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.6K | ★ 531.4K |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.53 | N/A |
| Revenue | ★ $178,000,000.00 | N/A |
| Revenue This Year | $11.25 | N/A |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | $8.82 | ★ N/A |
| Revenue Growth | ★ 16.49 | N/A |
| 52 Week Low | $23.89 | $0.95 |
| 52 Week High | $53.69 | $9.08 |
| Indicator | NCSM | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 59.09 |
| Support Level | $39.00 | $2.20 |
| Resistance Level | $40.69 | $3.56 |
| Average True Range (ATR) | 1.51 | 0.25 |
| MACD | -0.20 | 0.10 |
| Stochastic Oscillator | 13.36 | 63.60 |
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.